Media Examine Fight Against Counterfeit Drugs
Main Category: Pharma Industry / Biotech IndustryAlso Included In: Public Health
Article Date: 18 Feb 2010 - 4:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
The Wall Street Journal reports on the recent shutdown of a counterfeit drug ring in Syria, while highlighting a broader problem with counterfeit medicines in the Middle East. Authorities intercepted "millions of dollars worth of breast cancer, leukemia and other medicines ... At least 65 people were detained; it couldn't be learned if they were charged. A trial date hasn't yet been set," according to the newspaper, which notes that the drug ring distributor's activities had also penetrated into some public health systems, "particularly in Iraq."
The Syrian Health Minister Reda Saed said a significant portion of the fake drugs came from China. Officials said the Syrian operation was one of the main drug rings in the country, the newspaper writes. According to the Wall Street Journal, "Smuggling of drugs remains a widespread and dangerous problem. Figures from the World Health Organization show it can reach 35% of all drugs in the Middle East, compared to less than 1% in the U.S. and Western Europe."
The article also looks at how the sophistication of counterfeit networks and the absence of certain laws help fake drug networks thrive in the Middle East (Faucon, 2/15).
In related news, a Pfizer-sponsored study, published on Tuesday, found that "Western Europeans spend an estimated 10.5 billion euros ($14.3 billion) a year on illicitly sourced medicines, many of them counterfeit," Reuters reports. "Jim Thomson, chairman of the European Alliance for Access to Safe Medicines, which receives funding from the drug industry, said tests by his group had shown that 62 percent of medicines purchased online were fake or substandard," according to the news service.
Reuters also notes that "counterfeit medicines often contain the wrong or even toxic ingredients and are a growing health threat worldwide, especially in poor countries, according to the World Health Organization" (Hirschler, 2/16).
A related story by Lancet World Report says that "India, the leading supplier of low-cost generic drugs to Africa, has begun fighting back to counter the confusion surrounding counterfeit drugs in the region." According to the Lancet, India has asked Kenya to make changes to a recent law that some critics say "blurs the distinctions between generic, substandard, and counterfeit drugs" and could set a precedent for other African countries (Chatterjee, 2/13).
This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org.
© Henry J. Kaiser Family Foundation. All rights reserved.
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/179538.php>
APA
http://www.medicalnewstoday.com/releases/179538.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



